First Wave Biopharma Stock Working Capital
| FWBIDelisted Stock | USD 0.61 0.03 4.69% |
First Wave BioPharma fundamentals help investors to digest information that contributes to First Wave's financial success or failures. It also enables traders to predict the movement of First Stock. The fundamental analysis module provides a way to measure First Wave's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to First Wave stock.
First |
First Wave BioPharma Company Working Capital Analysis
First Wave's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current First Wave Working Capital | 1.82 M |
Most of First Wave's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, First Wave BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, First Wave BioPharma has a Working Capital of 1.82 M. This is 99.57% lower than that of the Biotechnology sector and 99.66% lower than that of the Health Care industry. The working capital for all United States stocks is 99.88% higher than that of the company.
First Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses First Wave's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of First Wave could also be used in its relative valuation, which is a method of valuing First Wave by comparing valuation metrics of similar companies.First Wave is currently under evaluation in working capital category among its peers.
First Fundamentals
| Return On Equity | -0.15 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 72.56 M | |||
| Shares Outstanding | 2.03 M | |||
| Shares Owned By Insiders | 5.66 % | |||
| Shares Owned By Institutions | 1.46 % | |||
| Number Of Shares Shorted | 46.6 K | |||
| Price To Book | 1.87 X | |||
| EBITDA | (15.74 M) | |||
| Net Income | (15.79 M) | |||
| Cash And Equivalents | 1.16 M | |||
| Cash Per Share | 0.83 X | |||
| Total Debt | 826.84 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | 7.99 X | |||
| Cash Flow From Operations | (12.38 M) | |||
| Short Ratio | 1.02 X | |||
| Earnings Per Share | (47.88) X | |||
| Target Price | 36.0 | |||
| Beta | 1.28 | |||
| Market Capitalization | 5.99 M | |||
| Total Asset | 6.88 M | |||
| Retained Earnings | (184.33 M) | |||
| Working Capital | 1.82 M | |||
| Net Asset | 6.88 M |
About First Wave Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze First Wave BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of First Wave using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of First Wave BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in First Stock
If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |